Oncology and Hematology News and Journal Articles
A new study provides evidence that a daily aspirin may reduce the risk of developing pancreatic cancer.
A combination of the CDK4 inhibitor palbociclib with ibrutinib in mantle cell lymphoma could potentially overcome the drug resistance that many patients face.
Each person facing cancer has their own way of coping. They have no obligation to fit a stereotype that others may have conjured up. They are each the poster child of their own unique campaign.
A new study from The Cancer Genome Atlas proposes a new classification of gastric cancers into four genomic subtypes that could eventually yield better treatment paradigms.
Patient navigators can play an important role in helping poor and underserved women overcome barriers to receiving recommended care for breast cancer, a recent study found.
Combining the EGFR inhibitors afatinib and cetuximab resulted in clinical responses among advanced lung cancer patients who had previously stopped responding to monotherapy treatment with other EGFR inhibitors.
Results of a head-to-head comparison of first-line treatment of metastatic renal cell carcinoma with the mTOR inhibitor everolimus or VEGF inhibitor sunitinib showed that everolimus did not meet noninferiority requirements as a first-line therapy.
A 3-year pilot program that rewarded oncologists for improving outcomes and efficiency—rather than administering drugs—significantly reduced overall costs without lowering quality of care.
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.
In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.
Dr. Katz describes how he uses social media to learn more about patient perceptions of cancer, how to decide which social media to use, and drawbacks to using social media in a professional capacity.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
In light of the recent FDA approval of HPV testing for women as a screening method for cervical cancer, we discuss changing guidelines with two experts.
As part of our coverage of the 2014 ASCO Annual Meeting, we discuss treatment strategies for breast cancer patients who harbor either the BRCA1 or BRCA2 mutation.
As part of our coverage of ASCO's Annual Meeting, we discuss the role of chemotherapy in prostate cancer, as well as study results on novel targeted approaches and agents in development for prostate cancer that will be presented at the meeting.
As part of our coverage of the ASCO Annual Meeting, we discuss advances in the management of upper gastrointestinal (GI) tract tumors, as well as highlighting clinical trial results that will be reported at the meeting.